医学
成像生物标志物
放射科
生物标志物
临床意义
疾病
回顾性队列研究
内科学
肿瘤科
磁共振成像
进行性疾病
肿瘤进展
临床试验
实体瘤疗效评价标准
试验预测值
正电子发射断层摄影术
病变
核医学
总体生存率
原发性肿瘤
转移
栓塞
临床实习
靶病变
功能成像
阶段(地层学)
无进展生存期
作者
Daniel Martinez Heinemann,Jannis H. Bodden,Lukas Endrös,Felianty Teresa,Manuel Nickel,Sebastian Lange,Markus Mergen,Daniel Spitzl,Roland Michael Schmid,Marc Martignoni,Jan Stefan Kirschke,Matthias Eiber,Rickmer Braren,Lisa Steinhelfer
标识
DOI:10.1007/s00259-026-08051-6
摘要
PURPOSE: In patients with liver-dominant metastatic disease undergoing yttrium-90 (⁹⁰Y) transarterial radioembolization (TARE), response assessment remains challenging, particularly in multifocal disease where manual RECIST-based measurements may not adequately reflect overall hepatic tumor burden. In addition, the prognostic relevance of volumetric changes in tumor, liver, and spleen after TARE remains unclear. This retrospective study evaluated automated CT-based whole-liver tumor volumetry as a quantitative imaging biomarker for response assessment and progression risk stratification following TARE. METHODS: We retrospectively analyzed imaging and clinical data from 57 adults with liver-dominant metastatic disease (colorectal, neuroendocrine, uveal melanoma, and breast cancer) treated with yttrium-90 (⁹⁰Y) resin TARE between January 2012 and December 2022. Inclusion criteria were age ≥ 18 years, availability of baseline contrast-enhanced CT imaging, and clinical follow-up. Patients undergoing liver resection, transplantation, or additional locoregional therapies during follow-up were excluded. RESULTS: Baseline tumor volume was a strong independent predictor of progression-free survival (PFS), demonstrating excellent discriminatory performance (ROC-AUC 0.91; 95% CI 0.82-1.00). A threshold of 270 mL most accurately identified early progression (< 12 months), with a sensitivity of 0.84 and specificity of 0.92. In contrast, lesion count, embolization strategy, and maximum tumor diameter were not significantly associated with PFS. CONCLUSIONS: Automated baseline tumor volumetry demonstrated promising prognostic performance compared with conventional clinical and procedural parameters in patients with liver-dominant metastases treated with ⁹⁰Y TARE. Automated quantification of intrahepatic tumor burden may serve as a useful and readily accessible imaging biomarker for early risk stratification, although external validation is required before clinical implementation.
科研通智能强力驱动
Strongly Powered by AbleSci AI